A multi-centre, pragmatic, three-arm, individually randomised, non-inferiority, open trial to compare immediate orally administered, immediate topically administered or delayed orally administered antibiotics for acute otitis media with discharge in children: The Runny Ear Study (REST): study protocol.


Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
03 Jun 2020
Historique:
received: 27 03 2020
accepted: 14 05 2020
entrez: 5 6 2020
pubmed: 5 6 2020
medline: 16 2 2021
Statut: epublish

Résumé

Acute otitis media (AOM) is a common painful infection in children, with around 2.8 million cases presenting to primary care in England and Wales annually. Nearly all children who present to their general practitioner (GP) with AOM or AOM with discharge (AOMd) are treated with orally administered antibiotics. These can cause side effects; contribute to the growing problem of antimicrobial resistance, and more rarely, allergic reactions. Alternative treatments, such as an antibiotic eardrops, or 'delayed' orally administered antibiotics, could be at least as effective and safe as immediate orally administered antibiotics for children with AOMd. REST is a pragmatic, three-arm, individually randomised, non-inferiority trial being conducted in 175 GP practices across the United Kingdom (UK). The study aims to recruit 399 children aged (≥ 12 months and < 16 years) presenting to their GP with AOMd. Children will be randomised to one of three arms: immediate ciprofloxacin 0.3% eardrops; delayed orally administered amoxicillin (clarithromycin if penicillin allergic) or immediate orally administered amoxicillin (clarithromycin). Recruitment, including eligibility screening, randomisation and data collection, are conducted using the innovative, TRANSFoRm electronic trial management platform. Integrated within the primary care electronic medical records it provides automatic eligibility checking, part-filling of e-CRFs, study workflow management and routine NHS follow-up data collection. The primary outcome is time to resolution of all significant symptoms and will be collected by the parent using a Symptom Recovery Questionnaire (SRQ). Secondary outcomes, including cost-effectiveness, duration of moderately bad or worse symptoms and repeat AOMd episodes, will be collected at day-14 and at 3 months. It is unclear whether prescribing orally administered antibiotics to children with AOMd results in a reduction in symptoms or a shorter duration of illness. The REST trial should allow us to compare the non-inferiority of: immediate topically administered ciprofloxacin ear drops, or delayed orally administered amoxicillin (clarithromycin) against immediate orally administered amoxicillin (clarithromycin). We aim to recruit 399 patients from 175 practices in the UK. Using the TRANSFoRm software to randomise participants to the trial will enable recruitment for a relatively uncommon condition. Name of Registry: ISCRTN Registration Number: ISRCTN12873692. This contains all items required to comply with the World Health Organization Trial Registration Data Set Date of Registration: 24 April 2018 Name of Registry: EudraCT Registration Number: 2017-003635-10 Date of Registration: 6 September 2017.

Sections du résumé

BACKGROUND BACKGROUND
Acute otitis media (AOM) is a common painful infection in children, with around 2.8 million cases presenting to primary care in England and Wales annually. Nearly all children who present to their general practitioner (GP) with AOM or AOM with discharge (AOMd) are treated with orally administered antibiotics. These can cause side effects; contribute to the growing problem of antimicrobial resistance, and more rarely, allergic reactions. Alternative treatments, such as an antibiotic eardrops, or 'delayed' orally administered antibiotics, could be at least as effective and safe as immediate orally administered antibiotics for children with AOMd.
METHODS/DESIGN METHODS
REST is a pragmatic, three-arm, individually randomised, non-inferiority trial being conducted in 175 GP practices across the United Kingdom (UK). The study aims to recruit 399 children aged (≥ 12 months and < 16 years) presenting to their GP with AOMd. Children will be randomised to one of three arms: immediate ciprofloxacin 0.3% eardrops; delayed orally administered amoxicillin (clarithromycin if penicillin allergic) or immediate orally administered amoxicillin (clarithromycin). Recruitment, including eligibility screening, randomisation and data collection, are conducted using the innovative, TRANSFoRm electronic trial management platform. Integrated within the primary care electronic medical records it provides automatic eligibility checking, part-filling of e-CRFs, study workflow management and routine NHS follow-up data collection. The primary outcome is time to resolution of all significant symptoms and will be collected by the parent using a Symptom Recovery Questionnaire (SRQ). Secondary outcomes, including cost-effectiveness, duration of moderately bad or worse symptoms and repeat AOMd episodes, will be collected at day-14 and at 3 months.
DISCUSSION CONCLUSIONS
It is unclear whether prescribing orally administered antibiotics to children with AOMd results in a reduction in symptoms or a shorter duration of illness. The REST trial should allow us to compare the non-inferiority of: immediate topically administered ciprofloxacin ear drops, or delayed orally administered amoxicillin (clarithromycin) against immediate orally administered amoxicillin (clarithromycin). We aim to recruit 399 patients from 175 practices in the UK. Using the TRANSFoRm software to randomise participants to the trial will enable recruitment for a relatively uncommon condition.
TRIAL REGISTRATION BACKGROUND
Name of Registry: ISCRTN Registration Number: ISRCTN12873692. This contains all items required to comply with the World Health Organization Trial Registration Data Set Date of Registration: 24 April 2018 Name of Registry: EudraCT Registration Number: 2017-003635-10 Date of Registration: 6 September 2017.

Identifiants

pubmed: 32493407
doi: 10.1186/s13063-020-04419-7
pii: 10.1186/s13063-020-04419-7
pmc: PMC7268414
doi:

Substances chimiques

Anti-Bacterial Agents 0
Amoxicillin 804826J2HU

Types de publication

Clinical Trial Protocol Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

463

Subventions

Organisme : Department of Health
ID : 16/85/01
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K025643/1
Pays : United Kingdom
Organisme : Health Technology Assessment Programme
ID : 16/85/01

Références

Nurse Res. 2006 Jul 1;13(4):84
pubmed: 27702218
Biomed Res Int. 2015;2015:961526
pubmed: 26539547
Lancet. 2006 Oct 21;368(9545):1429-35
pubmed: 17055944
Fam Pract. 2005 Aug;22(4):367-74
pubmed: 15897210
Arch Otolaryngol Head Neck Surg. 2004 Jun;130(6):705-9
pubmed: 15210550
Lancet. 2005 Feb 12-18;365(9459):579-87
pubmed: 15708101
Arch Pediatr Adolesc Med. 2000 Apr;154(4):395-400
pubmed: 10768680
Br J Gen Pract. 2006 Mar;56(524):170-5
pubmed: 16536956
BMC Fam Pract. 2008 Jan 31;9:10
pubmed: 18237423
J Public Health (Oxf). 2004 Sep;26(3):268-74
pubmed: 15454595
BMJ. 2010 May 18;340:c2096
pubmed: 20483949
Br J Gen Pract. 2005 Aug;55(517):603-8
pubmed: 16105368
Vaccine. 2010 Nov 19;28 Suppl 6:G39-52
pubmed: 21075269
J Allergy Clin Immunol. 2009 Nov;124(5):982-9
pubmed: 19895986
Res Nurs Health. 1995 Apr;18(2):179-83
pubmed: 7899572
BMJ. 1995 Jul 22;311(6999):251-3
pubmed: 7627048
N Engl J Med. 2014 Feb 20;370(8):723-33
pubmed: 24552319
Br J Gen Pract. 2010 Feb;60(571):101-5
pubmed: 20132703
JAMA. 2005 Jun 22;293(24):3029-35
pubmed: 15972565
BMJ. 2008 Sep 09;337:a1490
pubmed: 18782838
BMJ. 1997 Mar 8;314(7082):722-7
pubmed: 9116551
BMJ. 2001 Feb 10;322(7282):336-42
pubmed: 11159657
Pediatrics. 2015 May;135(5):e1182-9
pubmed: 25896832

Auteurs

Kathryn Curtis (K)

Centre for Academic Primary Care, Population Health Sciences, Bristol Medical School, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS82PS, UK.

Michael Moore (M)

Primary Care, Population Sciences and Medical Education, Faculty of Medicine, University Of Southampton, Southampton, SO17 1BJ, UK.

Christie Cabral (C)

Centre for Academic Primary Care, Population Health Sciences, Bristol Medical School, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS82PS, UK.

Vasa Curcin (V)

School of Population Health and Environmental Sciences, Faculty of Life Sciences and Medicine, King's College London, Addison House 3.07, Guy's Campus, London, SE1 1UL, UK.

Jeremey Horwood (J)

Centre for Academic Primary Care, Population Health Sciences, Bristol Medical School, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS82PS, UK.

Richard Morris (R)

Centre for Academic Primary Care, Population Health Sciences, Bristol Medical School, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS82PS, UK.

Vibhore Prasad (V)

School of Population Health and Environmental Sciences, Faculty of Life Sciences and Medicine, King's College London, Addison House 3.07, Guy's Campus, London, SE1 1UL, UK.

Anne Schilder (A)

evidENT, UCL Ear Institute, Royal National Throat, Nose and Ear Hospital, 330 Grays Inn Road, London, WC1X 8DA, UK.

Nicholas Turner (N)

Bristol Randomised Trial Collaboration (BRTC), part of the Bristol Trial Centre, Bristol Medical School, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS82PS, UK.

Scott Wilkes (S)

School of Medicine, Faculty of Health Sciences and Wellbeing, University of Sunderland, Sciences Complex, City Campus, Chester Road, Sunderland, SR1 3SD, UK.

Alastair D Hay (AD)

Centre for Academic Primary Care, Population Health Sciences, Bristol Medical School, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS82PS, UK.

Jodi Taylor (J)

Bristol Randomised Trial Collaboration (BRTC), part of the Bristol Trial Centre, Bristol Medical School, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS82PS, UK. j.taylor@bristol.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH